Skip to main content

Keppra-XR Dosage

Generic name: LEVETIRACETAM 500mg
Dosage form: tablet, film coated, extended release
Drug class: Pyrrolidine anticonvulsants

Medically reviewed by Drugs.com. Last updated on Mar 14, 2024.

Recommended Dosing

For adults and adolescent patients, the recommended dosing for monotherapy and adjunctive therapy is the same; as outlined below.

Adults and Adolescents 12 Years of Age and Older Weighing 50 kg or More

Initiate treatment with a dose of 1000 mg once daily. The once daily dosage may be adjusted in increments of 1000 mg every 2 weeks to a maximum recommended daily dose of 3000 mg/day once daily.

Administration

KEPPRA XR is administered once daily. KEPPRA XR tablets should be swallowed whole. The tablets should not be chewed, broken, or crushed.

Dosage Adjustments in Adult Patients with Renal Impairment

KEPPRA XR dosing must be individualized according to the patient's renal function status. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this, an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

CLcr= [140-age (years)] × weight (kg)
--------------------------------------
(× 0.85 for female patients)
72 × serum creatinine (mg/dL)

Then CLcr is adjusted for body surface area (BSA) as follows:

CLcr (mL/min/1.73m2)= CLcr (mL/min)
-------------------------
× 1.73
BSA subject (m2)
Table 1: Dosage Adjustment Regimen for Adult Patients with Renal Impairment
Group Creatinine Clearance
(mL/min/1.73m2)
Dosage
(mg)
Frequency
Normal > 80 1000 to 3000 Every 24 hours
Mild 50 – 80 1000 to 2000 Every 24 hours
Moderate 30 – 50 500 to 1500 Every 24 hours
Severe < 30 500 to 1000 Every 24 hours

Discontinuation of KEPPRA XR

Avoid abrupt withdrawal from KEPPRA XR in order to reduce the risk of increased seizure frequency and status epilepticus [see Warnings and Precautions (5.8)].

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.